

Index

- AA amyloidosis, 159–62
- AAV. *See* ANCA-associated vasculitis
- ABMR. *See* antibody-mediated rejection
- absent kidney, 4–5, 8–9
- acid sphingomyelinase deficiency, 133.
See also Niemann-Pick disease
- actin-binding complexes, podocyte, 44–8
- active ABMR, 345, 350
- ACTN4 mutations, 44
- acute interstitial nephritis, incidence of, 20
- acute kidney injury (AKI)
acute TIN presenting with, 181
COVID-19 with, 240–1
dengue fever with, 239–40
Hantavirus with, 231–9
leishmaniasis with, 249–51
Leptospira infections with, 246–7
malarial, 243–5
nephrotic syndrome with, 29
pediatric tumor treatment associated with, 333–4
post-transplant, 343
Rickettsia infections with, 247–8
- acute post *Staphylococcus aureus* GN (APSGN), 92
- acute TCMR, 351
- acute tubular injury (ATI)
incidence of, 20
post-transplant, 343
- acute tubular necrosis (ATN), post-transplant, 343
- ACys. *See* cystatin C amyloidosis
- ADAMTS13 antibody mediated TTP, 222–5
- adenine phosphoribosyltransferase (APRT) deficiency, 197, 199, 202–3, 208
- adenovirus, post-transplant infection with, 356–7
- ADPKD. *See* autosomal dominant polycystic kidney disease
- ADTKD. *See* autosomal dominant tubulointerstitial kidney disease
- adult type polycystic kidney disease. *See* autosomal dominant polycystic kidney disease
- adults, renal biopsy diagnoses in children versus, 17
- AFib. *See* fibrinogen A α -chain amyloidosis
- agenesis, renal, 4–5, 8–9
- AGXT mutations, 197–8
- AKI. *See* acute kidney injury
- AL amyloidosis, 159, 162–3
- Alagille syndrome, 140–2
- alanine-glyoxylate aminotransferase deficiency, 197–8, 207–8
- aldolase A deficiency, 144
- alkaptonuric ochronosis, 150–1
- allergic TIN
epidemiology, clinical findings and etiology of, 181–2
microscopy and immunofluorescence of, 182–4
therapy and prognosis of, 183
- allograft biopsy. *See also* transplant pathology
distribution of diagnoses made with, 23–4
processing of, 342–3
types of, 341–2
- allopurinol, 208
- alpha-galactosidase A deficiency, 123–5.
See also Fabry disease
- Alport syndrome (AS), 56–7, 66–7
clinical symptoms of, 59–63
definitions for, 57
electron microscopy of, 62–5, 68
genetic tests for, 65–78
immunofluorescence of, 61–4, 68
incidence of, 19
knowledge gaps in, 67
light microscopy of, 61, 63–4, 68
pathogenesis and inheritance of, 57–9
prognosis and therapy of, 65–6
TBMN compared with, 67–72
- AMLEC. *See* angiomyolipoma with epithelial-lined cyst
- amphotericin B, 249, 251
- amyloidoses, 159
AA, 159–62
ACys, 159
AFib, 159, 162–3
AL, 159, 162–3
clinical presentation of, 162
definition of, 159–60
electron microscopy of, 162–3
immunofluorescence of, 162
light microscopy of, 161–3
mass spectrometry of, 163
pathogenesis of, 161–2
stains for detection of, 159–63
treatment and prognosis of, 163
- anaplasia, in WT, 304, 306–9, 314
- anaplastic sarcoma of kidney (ASK), 327–31
- ANCA-associated vasculitis (AAV), 219
ancillary laboratory tests for, 219
classification and scoring of, 219
clinical symptoms of, 214
definition of, 213
electron microscopy of, 215, 218–19
immunofluorescence and immunohistochemistry of, 214–18
knowledge gaps in, 220
light microscopy of, 214–18
pathophysiology of, 213–14
prognosis and therapy of, 219
- anemia
hemolytic, 220
sickle cell, 151–5
- angiomyolipoma with epithelial-lined cyst (AMLEC), 276–8
- angiomyolipomas, 272–4, 280
ancillary laboratory tests for, 277–9
gross pathology of, 274–5
microscopic features of, 274–8
treatment of, 279–80
- angiomyolipomatosis, 275–6
- ANKFY1 mutations, 48
- ANLN mutations, 44
- antenatal ultrasound
of ADPKD, 259–60
of ARPKD, 266
of CAKUT, 8
- antibody-mediated rejection (ABMR)
Banff classification of, 350–1
distribution of allograft biopsies with, 23–4

Index

- antibody-mediated rejection (ABMR) (cont.)
immunologic background and mechanisms of, 345
- anti-GBM antibodies, 66, 213–14
- anti-GBM disease, 219
ancillary laboratory tests for, 219
classification and scoring of, 219
clinical symptoms of, 214
definition of, 213
electron microscopy of, 215, 218–19
immunofluorescence and immunohistochemistry of, 214–18
knowledge gaps in, 220
light microscopy of, 214–18
pathophysiology of, 213–14
prognosis and therapy of, 219
- antithymocyte globulin, 351
- aplasia, renal, 4–5, 8–9
- ApoE. *See* apolipoprotein E
- APOL1* mutations, 41
- APOL1*-associated nephropathy, 18–19
- apolipoprotein E (ApoE), glomerular disorders related to, 136
ApoE2 homozygote glomerulopathy, 136
LPG, 136–9
- APRT deficiency. *See* adenine phosphoribosyltransferase deficiency
- APSGN. *See* acute post *Staphylococcus aureus* GN
- ARHGAP24* mutations, 44
- ARHGDI1* mutations, 47
- ARPKD. *See* autosomal recessive polycystic kidney disease
- arterial hypertension. *See* hypertension
- arterial intimal fibrosis of new onset, 354–5
- arteriolar hyalinization
calcineurin inhibitor associated, 362–3
de novo post-transplant, 355–6
arteriosclerosis, de novo post-transplant, 354–5
- arteriovenous malformation (AVM), 225–6
- artesian, 244–5
- AS. *See* Alport syndrome
- ASK. *See* anaplastic sarcoma of kidney
- Ask-Upmark kidney, 11
- ATI. *See* acute tubular injury
- ATN. *See* acute tubular necrosis
- atypical PIGN, 93–4
- autosomal Alport syndrome, 57–9
clinical symptoms of, 60–2
collagen IVα5 staining in, 61, 64
TBMN compared with, 67–9, 71–2
- autosomal dominant polycystic kidney disease (ADPKD), 255, 268
clinical signs and symptoms of, 257–61
definitions and terminology for, 255
diagnostic criteria for, 258, 260
genetics of, 255–8
glomerular cysts in, 262–3, 286–7
gross pathology of, 261–2
knowledge gaps in, 269
laboratory testing for, 259
liver pathology in, 260, 262
microscopic features of, 262–4
prognosis and therapy of, 263
radiographic imaging of, 259–60
very early onset, 256–7, 259
- autosomal dominant tubulointerstitial kidney disease (ADTKD), 190, 290, 296
clinical symptoms and histopathology of, 291–5
definition of, 290
genetics of, 290–5
gross pathology of, 295
knowledge gaps in, 296–7
microscopic features of, 293, 295–6
mitochondrial kidney disease compared with, 176
prognosis and therapy of, 296
- autosomal recessive polycystic kidney disease (ARPKD), 263–4, 268
clinical signs and symptoms of, 265–7
definitions and terminology for, 255
genetics of, 256, 264–5
glomerular cysts in, 286–7
gross pathology of, 267–8
knowledge gaps in, 269
microscopic features of, 267–8
prognosis and therapy of, 267–8
radiographic imaging of, 266
- avacopan, 213–14, 219
- AVIL* mutations, 47
- AVM. *See* arteriovenous malformation
- bacteria
direct kidney infections with, 231–3
Leptospira, 246–7
Rickettsia, 247–8
Treponema pallidum, 247
tuberculosis, 231–4
post-transplant infection with, 248
Cryptococcus neoformans, 247–9
Leishmania donovani, 249–51
pyelonephritis, 356
- Banff classification of transplant rejection, 345
histopathological scores according to revised 2019, 345–50
- polyomavirus nephropathy, 359–61
rejection categories according to revised 2019, 350–1
- Bardet-Biedl syndrome (BBS), 285–9
- Bardoxolone, 65
- Barisoni Lipid Inclusions Scoring System (BLISS), 129
- Bartter's syndrome
epidemiology, clinical findings and etiology of, 191, 193
light microscopy of, 193
therapy and prognosis of, 193
- Batten disease, 135–7
- BBS. *See* Bardet-Biedl syndrome
- BCOR* rearrangements, 299, 316–19
- Beckwith Wiedemann syndrome, 300–3
- benign familial haematuria. *See* thin basement membrane nephropathy
- benign nephrosclerosis, 226–7
- benznidazole, 246
- beta-galactosidase deficiency, 133, 135
- bile cast nephropathy, 197, 209
clinical symptoms of, 199–200
gross pathology of, 201
light microscopy of, 205, 207
prognosis and therapy of, 208–9
- bilharziasis. *See* *Schistosoma*
- biopsy. *See* transplant biopsy; *specific diseases*
- biopsy incidence of renal diseases. *See* incidence of renal diseases
- BK virus, 358–61
- blastema, of WT, 306–13
- BLISS. *See* Barisoni Lipid Inclusions Scoring System
- blood pressure, percentiles, 225
- borderline acute TCMR, 351
- Bortezomib, antirejection treatment with, 351
- BRAF V600E* mutations, 331–3
- C1q nephropathy, 99–111, 115
clinical symptoms of, 111
definition of, 111
HIVAN with, 235–7
microscopic features of, 111–12
prognosis and therapy of, 112
- C3 glomerulonephritis (C3GN), 98–100, 114–15
clinical symptoms of, 100
definition of, 99
incidence of, 19
microscopic features of, 94–101
PIGN compared with, 93
prognosis and therapy of, 101–2
- C5a peptide, 213–14
- C5aR1 receptor, 213–14
- C5b-9, 220, 222–5

- CAKUT. *See* congenital anomalies of kidneys and urinary tract
- calcineurin inhibitors (CNIs), nephrotoxicity of, 362–3
- calcium oxalate crystals. *See* oxalate nephropathy
- calcium phosphate crystals. *See* nephrocalcinosis
- calcium signaling, podocyte, 46–7
- caplacizumab, 222–5
- carbohydrate metabolism disorders. *See* glycogen, glucoprotein and carbohydrate metabolism disorders
- cardiac rhabdomyoma, 272–4
- CCSK. *See* clear cell sarcoma of kidney
- CD2AP* mutations, 44
- cellular subtype FSGS, 30–3
- CGD. *See* congenital glycosylation disorders
- CGP. *See* collapsing glomerulopathy
- Chagas disease, 245–6
- cholemic nephrosis, 197, 199–200
- chromatin, dysregulation of, 299
- chronic ABMR, 345, 351
- chronic active ABMR, 345, 350–1
- chronic active TCMR, 351
- chronic ischemic glomerulopathy, 353–4
- chronic kidney disease (CKD). *See also specific diseases*
- pediatric tumor treatment associated with, 333–4
- chronic TCMR, 345
- Churg-Strauss syndrome. *See* eosinophilic granulomatosis with polyangiitis
- ciliopathies, 4–5, 11. *See also* nephronophthisis
- CKD. *See* chronic kidney disease
- clear cell sarcoma of kidney (CCSK), 310–33
- CLN* mutations, 135–6
- CMN. *See* congenital mesoblastic nephroma
- CMV. *See* cytomegalovirus
- CNF. *See* congenital nephrotic syndrome of the Finnish type
- CNIs. *See* calcineurin inhibitors
- CNS. *See* congenital nephrotic syndrome
- CNS type 2. *See* congenital nephrotic syndrome type 2
- coagulation disorders. *See* thrombotic microangiopathy
- cobalamin C deficiency, 220, 222–5
- cobalamin therapy, 148
- coenzyme Q2 (CoQ2) deficiency, 175–6
- coenzyme Q₁₀ (CoQ10) deficiency, 48, 175–6
- COL4A3*, *COL4A4* and *COL4A5* mutations, 56–9, 65–78
- COL4A3* and *COL4A4* mutations, 67–9, 71–2
- collagen IV α 5 staining, 61–4, 68
- collagenofibrotic glomerulopathy. *See* type III collagenopathy
- collagenopathies. *See* hematuric glomerular diseases
- collapsing glomerulopathy (CGP), 41, 43
- ancillary laboratory tests for, 42–3
- clinical symptoms of, 41
- collapsing subtype FSGS, 30–1
- de novo post-transplant, 353–4
- definitions for, 41
- HIVAN with, 41–2, 235–7
- incidence of, 18–19
- knowledge gaps in, 43
- microscopy and immunofluorescence of, 41–2
- mitochondrial disease with, 175–6
- prognosis and therapy of, 43
- PVB19-associated, 237–8
- collecting ducts, 1
- normal development of, 3, 6–7
- computerized tomography (CT), of ADPKD, 259–60
- congenital anomalies of kidneys and urinary tract (CAKUT), 1, 7–9, 13
- absent kidneys, 4–5, 8–9
- antenatal ultrasound of, 8
- cystic kidney diseases and ciliopathies, 4–5, 8–9, 11, 255
- duplex kidneys, 8, 11–12
- dysplastic kidneys, 4–5, 8–12, 286–7
- ectopic kidneys and malrotation, 8–12
- hypoplastic kidneys, 4–5, 11
- microCT of, 9
- pathogenesis underlying
- genetic, 4–5, 12
- obstruction, 12
- teratogens and maternal factors, 12
- congenital glycosylation disorders (CGD), 145
- clinical features of, 146
- renal pathologic features of, 146
- congenital hereditary haematuria. *See* thin basement membrane nephropathy
- congenital membranous nephropathy, 105–6
- congenital mesoblastic nephroma (CMN), 310–33
- congenital nephrotic syndrome (CNS), 37, 41. *See also* Pierson syndrome
- ancillary laboratory tests for, 40
- clinical symptoms of, 39
- definitions for, 37–9
- genetics of, 27–46, 49
- autosomal dominant conditions, 44–7
- autosomal recessive conditions, 47–9
- knowledge gaps in, 49
- knowledge gaps in, 41
- microscopy and immunofluorescence of, 38–40
- prognosis and therapy of, 40–1
- syphilis with, 247
- congenital nephrotic syndrome of the Finnish type (CNF), 18, 37–41
- congenital nephrotic syndrome type 2 (CNS type 2), 37–41
- Congo red stain, 159–63
- CoQ2 deficiency. *See* coenzyme Q2 deficiency
- CoQ10 deficiency. *See* coenzyme Q₁₀ deficiency
- core needle biopsy, 342–3
- Cori's disease, 144
- corneal lesions, in Alport syndrome, 59–63
- cortex, 1
- COVAN. *See* COVID-19 associated nephropathy
- COVID-19. *See* severe acute respiratory syndrome coronavirus 2
- COVID-19 associated nephropathy (COVAN), 18–19, 41–2
- CPDN. *See* cystic partially differentiated nephroblastoma
- CRB2* mutations, 47
- cross-fused ectopia, 8–9, 12
- Cryptococcus neoformans* infections, 247–9
- crystal deposits, tubulointerstitial diseases with, 197, 209
- clinical symptoms of, 197–9
- definitions for, 197
- gross pathology of, 201
- knowledge gaps in, 209
- light microscopy of, 201–3
- prognosis and therapy of, 206–8
- CT. *See* computerized tomography
- CTSA mutations, 143
- cyanocobalamin metabolism, 148
- cyclophosphamide, 219
- cyclosporin, nephrotoxicity of, 362–3
- cystatin C amyloidosis (ACys), 159
- cystic angiomyolipoma, 276–8
- cystic dysplasia, 4–5, 8–12, 286–7
- cystic kidney diseases, 4–5, 8–9, 11, 255. *See also* autosomal dominant polycystic kidney disease; autosomal recessive polycystic kidney disease

Index

- cystic kidney diseases (cont.)
 ADTKD, 190, 290, 296
 clinical symptoms and
 histopathology of, 291–5
 definition of, 290
 genetics of, 290–5
 gross pathology of, 295
 knowledge gaps in, 296–7
 microscopic features of, 293, 295–6
 mitochondrial kidney disease
 compared with, 176
 prognosis and therapy of, 296
 incidence of, 21
 NPH, 290–1, 296
 clinical symptoms and
 histopathology of, 290–2, 294
 definition of, 290
 gross pathology of, 295
 incidence of, 21
 knowledge gaps in, 296–7
 microscopic features of, 291–5
 prognosis and therapy of, 296
 TSC, 272, 280
 ancillary laboratory tests for,
 277–9
 clinical symptoms of, 272–4
 definitions for, 272
 gross pathology of, 274–5
 knowledge gaps in, 280
 microscopic features of,
 274–8
 prognosis and therapy of, 279–80
 cystic nephroma. *See* pediatric cystic
 nephroma
 cystic partially differentiated
 nephroblastoma (CPDN), 314–30
 cytomegalovirus (CMV), post-transplant
 infection with, 357–8
- DAH. *See* diffuse alveolar hemorrhage
 DDD. *See* dense deposit disease
 DDS. *See* Denys-Drash syndrome
dengue virus infections, 239–40
 dense deposit disease (DDD), 96–100,
 114–15
 clinical symptoms of, 100
 definition of, 99
 incidence of, 19
 microscopic features of, 94–101
 Dent disease, 21, 48
 Denys-Drash syndrome (DDS), 35, 47,
 300–3
 development, kidney. *See* nephrogenesis
 DHA nephropathy. *See* 2,8-
 dihydroxyadenine nephropathy
 diabetes mellitus (DM)
 in childhood and adolescence, 146–9
 maternal, 12
- diabetic kidney disease (DKD)
 clinical features of, 146–7
 incidence of, 17, 19–20
 pathogenetic mechanisms of, 147
 pathologic features of, 147–9
DICER1 mutations, 327–31
 diffuse alveolar hemorrhage (DAH), 214
 diffuse mesangial hypercellularity
 (DMH), 18, 29–30
 diffuse mesangial sclerosis (DMS), 18–19,
 33–7
 clinical symptoms of, 35
 definitions for, 35
 genetics of, 27–46
 knowledge gaps in, 37
 microscopy and immunofluorescence
 of, 35–7
 in Pierson syndrome, 78–9
 prognosis and therapy of, 37
 digenic Alport syndrome, 57–9
 2,8-dihydroxyadenine (DHA)
 nephropathy, 197, 209
 clinical symptoms of, 199
 light microscopy of, 202–3
 prognosis and therapy of, 208
 distal tubule, 1
 normal development of, 3, 5–6
 DKD. *See* diabetic kidney disease
 DM. *See* diabetes mellitus
 DMH. *See* diffuse mesangial
 hypercellularity
 DMS. *See* diffuse mesangial sclerosis
 DNA, mitochondrial, 171–3
 DNA-interacting proteins, podocyte,
 47–8
DNAJB9, 163–5
DNAJB11 mutations, 255–7
 donor biopsy, 342–3
 donor specific antibodies (DSAs), 344
 drug-induced TIN
 epidemiology, clinical findings and
 etiology of, 181–2
 microscopy and immunofluorescence
 of, 182–4
 therapy and prognosis of, 183
 DSAs. *See* donor specific antibodies
 duplex kidneys, 8, 11–12
 dysplastic kidney, 4–5, 8–12, 286–7
DZIP1L mutations, 256, 264–6
- ectopic kidneys, 8–12
 eculizumab, 213–14, 222–5, 351
 EGPA. *See* eosinophilic granulomatosis
 with polyangiitis
 EHEC. *See* enterohemorrhagic *Escherichia*
coli
 elbow abnormalities, in NPS, 73–5
EMP2 mutations, 48
- emphysematous pyelonephritis, 186
 end stage renal disease (ESRD)
 ADPKD with, 258
 ARPKD with, 265–6
 kidney transplants for, 341
 NPH with, 290–1, 296
 endocarditis-associated GN, 95
 endowment, nephron, 1, 13
 enterohemorrhagic *Escherichia coli*
 (EHEC), 220, 222–5
 eosinophilic granulomatosis with
 polyangiitis (EGPA), 213–18
 erythrocytes, RBC casts compared with,
 205–6
 ESRD. *See* end stage renal disease
ETV6-NTRK3 fusion, 319–21
 everolimus, 279–80
 Ewing sarcoma. *See* primitive
 neuroectodermal tumor
 EXT1/EXT2 antigen, 105–6
EYA1 mutations, 66
- Fabry disease, 123–5
 clinical features of, 125–8
 differential diagnosis of, 129
 disease severity scoring systems for, 129
 renal pathological features of, 128–32
 therapy for, 130–1
 factor H deficiency, 81, 166, 220
 familial benign haematuria. *See* thin
 basement membrane nephropathy
 familial juvenile hyperuricemic
 nephropathy (FJHN), 290–3,
 295–6
 familial Mediterranean fever (FMF),
 159–62
FAN1 mutations, 190
 Fanconi syndrome, 122
 Fanconi-Bickel syndrome, 144–5
FAT1 mutations, 47
 FGN. *See* fibrillary glomerulonephritis
 fibrillary deposits, glomerular diseases
 with, 159, 169
 amyloidoses, 159–63
 collagenofibrotic glomerulopathy,
 80–3, 159, 166–8
 differential diagnosis for, 160
 FGN, 159, 163–5
 fibronectin glomerulopathy, 159, 166–7
 knowledge gaps in, 169
 fibrillary glomerulonephritis (FGN),
 163–4
 clinical presentation of, 164
DNAJB9 immunohistochemistry in,
 165
 electron microscopy of, 159–65
 immunofluorescence of, 164–5
 light microscopy of, 164–5

- pathogenesis of, 164
treatment and prognosis of, 165
- fibrinogen A α -chain amyloidosis (AFib), 159, 162–3
- fibrocystin, 264–5
- fibromuscular dysplasia (FMD), 21, 225–6
- fibronectin glomerulopathy, 166
clinical presentation of, 166
microscopy and immunofluorescence of, 166–7
pathogenesis of, 166
proteomics of, 166
treatment and prognosis of, 166
- Finnish type nephrotic syndrome. *See* congenital nephrotic syndrome of the Finnish type
- fish-eye disease, 139–57
- FJHN. *See* familial juvenile hyperuricemic nephropathy
- fluconazole, 249
- FMD. *See* fibromuscular dysplasia
- FMF. *See* familial Mediterranean fever
- focal segmental glomerulosclerosis (FSGS), 27–8, 34
ancillary laboratory tests for, 31–3
biopsy incidence of, 17–19
clinical symptoms of, 29
Columbia classification of, 30–3
de novo post-transplant, 353–4
definition of, 28–9
genetics of, 27–46, 49
autosomal dominant conditions, 44–7
autosomal recessive conditions, 47–9
knowledge gaps in, 49
HIVAN with, 235–7
knowledge gaps in, 34–5
microscopy and immunofluorescence of, 29–33
mitochondrial disease with, 175
prognosis and therapy of, 33–4
recurrent, 352–4
secondary
in AAV and anti-GBM disease, 214–18
in HTN, 226–7
types by causes of, 28
- Fong disease. *See* Nail-Patella syndrome
- Frasier syndrome, 35, 47, 300–3
- frequently relapsing nephrotic syndrome (FRNS), 28–9, 33–4
- FSGS. *See* focal segmental glomerulosclerosis
- fungi, direct kidney infections with, 232–3
- galactosialidosis, 143
clinical features of, 143
pathologic features of, 143–4
- Galloway-Mowat syndrome (GAMOS), 27–46, 48–9
- GANAB mutations, 255–7
- gangliosidosis, 133, 135
- GAPVD1 mutations, 48
- Gaucher disease, 132
clinical features of, 132
pathological features of, 132–3
- GB3. *See* globotriaosylceramide
- GBM. *See* glomerular basement membrane
- GCK/GCKD. *See* glomerulocystic kidney/glomerulocystic kidney disease
- GDNF/RET/GFRa system, 11–12
- genetics. *See also specific genes*
ADPKD, 255–8
ADTKD, 290–5
Alport syndrome, 57–9, 65–78
ARPKD, 256, 264–5
Bartter's syndrome, 191, 193
CAKUT, 4–5, 12
of GCK/GCKD, 283–7
HUS, 220, 225
mitochondrial kidney disease, 171–3
Nail-Patella syndrome, 65–78
oxalate nephropathy, 197–8
Pierson syndrome, 65–80
proteinuric glomerular disease, 27–46, 49
autosomal dominant conditions, 44–7
autosomal recessive conditions, 47–9
knowledge gaps in, 49
TBMN, 71–2
WT, 299–303
- ghost membranes, of RBC casts, 205–6
- GIN. *See* granulomatous interstitial nephritis
- GLA mutations, 123–5. *See also* Fabry disease
- globotriaosylceramide (GB3), 123–5. *See also* Fabry disease
- glomerular basement membrane (GBM), 27, 37. *See also* anti-GBM disease; hematuric glomerular diseases
collagen in, 56–7
laminins in, 77
thickness measurements of, 70–1
- glomerular cysts. *See* glomerulocystic kidney/glomerulocystic kidney disease
- glomerular diseases. *See also* hematuric glomerular diseases; immune complex mediated glomerular diseases; proteinuric glomerular diseases
de novo post-transplant, 352–6
with fibrillary deposits, 159, 169
- amyloidoses, 159–63
collagenofibrotic glomerulopathy, 80–3, 159, 166–8
differential diagnosis for, 160
FGN, 159, 163–5
fibronectin glomerulopathy, 159, 166–7
knowledge gaps in, 169
incidence of, 18–20
metabolic disease, 121–2
mitochondrial disease with, 175–6
pediatric tumor treatment associated with, 333–4
recurrent, 352–4
- glomerular filtration barrier, 27. *See also* proteinuric glomerular diseases
- glomerular microhamartomas, in TSC, 275
- glomerular necrosis, AAV and anti-GBM disease with, 213–19
- glomerulocystic kidney/glomerulocystic kidney disease (GCK/GCKD), 283, 288
acquired, 285
in ADPKD, 262–3, 286–7
in ARPKD, 286–7
clinical symptoms of, 284
BBS and RP, 285–9
familial ADGCKD, 284
MODY, 283–4
definition of, 283–4
differential diagnosis of, 283
genetics of, 283–7
gross pathology of, 285–6
knowledge gaps in, 288
light microscopy of, 285–7
pathogenesis of, 284
prognosis and therapy of, 287
in TSC, 275–6
- glomerulomegaly, incidence of, 20
- glomerulonephritis (GN). *See also* immune complex mediated glomerular diseases
anti-GBM disease with rapidly progressive, 214
- glomerulus, normal development of, 3, 5–6
- Glucantime, 251
- glucoprotein disorders. *See* glycogen, glucoprotein and carbohydrate metabolism disorders
- glucose-6-phosphatase deficiency, 144
- glucose-6-phosphate translocase deficiency, 144
- glycogen, glucoprotein and carbohydrate metabolism disorders, 122–3, 125
alkaptonuric ochronosis, 150–1
CGD, 145–6

Index

- glycogen, glucoprotein and carbohydrate metabolism disorders (cont.)
 childhood obesity and metabolic syndrome, 148, 150
 diabetes mellitus in childhood and adolescence, 146–9
 galactosialidosis, 143–4
 GSD, 143–5
 MMA, 148–50
 nephrosialidosis, 141–3
 glycogen storage diseases (GSD), 143
 type I, 144–5
 type III, 144
 type V, 144
 type XI, 144–5
 type XII, 144
 glycosylation disorders. *See* congenital glycosylation disorders
 glycosylceramidase deficiency, 132. *See also* Gaucher disease
 glyoxylate reductase–hydroxypyruvate reductase deficiency, 197–8, 207–8
 GM1 gangliosidosis, 133, 135
 GM2 gangliosidosis, 133
 GN. *See* glomerulonephritis
 GNPTAB and GNPTG mutations, 134
 Goodpasture syndrome, 213
 GPA. *See* granulomatosis with polyangiitis
 granulomas
 sarcoidosis, 188–9
Schistosoma, 241–3
 tuberculosis, 231–4
 granulomatosis with polyangiitis (GPA), 213–18
 granulomatous interstitial nephritis (GIN), incidence of, 20
 GRHPR mutations, 197–8
 GSD. *See* glycogen storage diseases

 HAdV. *See* human adenovirus
 Hall's stain, 197, 205, 207
 hamartin, 272, 277–9
 hamartomas, in TSC, 272–5
 Hantaviruses infections, 231–9
 hearing loss, in Alport syndrome, 59–63
 hematuria
 ADPKD with, 259
 IgA nephropathy with, 88
 hematuric glomerular diseases, 56
 Alport syndrome, 56–7, 66–7
 clinical symptoms of, 59–63
 definitions for, 57
 electron microscopy of, 62–5, 68
 genetic tests for, 65–78
 immunofluorescence of, 61–4, 68
 incidence of, 19
 knowledge gaps in, 67
 light microscopy of, 61, 63–4, 68
 pathogenesis and mode of inheritance of, 57–9
 prognosis and therapy of, 65–6
 TBMN compared with, 67–72
 Nail-Patella syndrome, 27–46, 72–3, 77
 clinical findings of, 73–5
 definition of, 73
 genetics of, 65–78
 knowledge gaps in, 77
 renal histopathology of, 74–6
 treatment and monitoring of, 76–7
 Pierson syndrome, 27–46, 77, 80
 clinical symptoms of, 78
 definition of, 77
 genetics of, 65–80
 knowledge gaps in, 80
 pathology of, 78–9
 treatment, monitoring, and prognosis of, 80
 TBMN, 67, 72
 clinical symptoms of, 67–9
 definition of, 67
 genetics of, 71–2
 incidence of, 19
 knowledge gaps in, 72
 microscopy and immunofluorescence of, 65, 69–71
 prognosis and therapy of, 72
 type III, 80–1, 83, 159, 166
 clinical symptoms of, 81, 166
 knowledge gaps in, 83
 pathogenesis of, 166
 pathology of, 81–3, 166–8
 prognosis and therapy of, 83, 167
 type III collagenopathy, 80–1, 83, 159, 166
 clinical symptoms of, 81, 166
 knowledge gaps in, 83
 pathogenesis of, 166
 pathology of, 81–3, 166–8
 prognosis and therapy of, 83, 167
 hemoglobin cast nephropathy, 197, 209
 clinical symptoms of, 200
 light microscopy of, 203–5
 prognosis and therapy of, 208
 hemoglobinopathies. *See* sickle cell disorders
 hemolysis. *See* hemoglobin cast nephropathy
 hemolytic uraemic syndrome (HUS), 220
 atypical, 220, 222–5
 clinical symptoms of, 220
 definitions for, 220
 electron microscopy of, 221–2
 immunofluorescence and immunohistochemistry of, 221–2
 incidence of, 21
 knowledge gaps in, 225
 light microscopy of, 220–2
 pathophysiology of, 220
 prognosis and therapy of, 222–5
 recurrent, 352, 354
 type III collagenopathy with, 81, 166
 Henoch Schönlein purpura nephritis (HSP), 17–18, 89, 91–116
 hepatic cysts, ADPKD with, 260, 262
 hepatic fibrosis, in ARPKD, 266–7
 hereditary haematuria. *See* thin basement membrane nephropathy
 hereditary osteonchodysplasia. *See* Nail-Patella syndrome
 heteroplasmy, in mitochondrial kidney disease, 172
 hexosaminidase deficiency, 133
 HIV. *See* human immunodeficiency virus
 HIV-associated nephropathy (HIVAN), 41–2, 235–7
 HNF1 β mutations, 283–4, 290–1, 295–6
 HOGA1 mutations, 197–8
 homogentisate 1.2 dioxygenase deficiency, 150–1
 homoplasmy, in mitochondrial kidney disease, 172
 horseshoe kidney, 10–12
 HSP. *See* Henoch Schönlein purpura nephritis
 HTN. *See* hypertension
 human adenovirus (HAdV), post-transplant infection with, 356–7
 human immunodeficiency virus (HIV)
 direct kidney infections with, 235–7
 nephropathy associated with, 41–2, 235–7
 opportunistic infections in, 248
Cryptococcus neoformans, 247–9
Leishmania donovani, 249–51
 HUS. *See* hemolytic uraemic syndrome
 hyaline arteriolopathy. *See* arteriolar hyalinization
 4-hydroxy-2-oxoglutarate aldolase deficiency, 197–8, 207–8
 hyperacute rejection, 344–5
 hypercalcemia. *See* nephrocalcinosis
 hyperfiltration-type injury, incidence of, 20
 hyperglycemia. *See* diabetic kidney disease
 hyperoxaluria. *See* oxalate nephropathy
 hyperphosphatemia. *See* nephrocalcinosis
 hypersensitivity reactions, TIN with
 epidemiology, clinical findings and etiology of, 181–2
 microscopy and immunofluorescence of, 182–4
 therapy and prognosis of, 183

- hypertension (HTN), 225, 229
ADPKD with, 259
clinical symptoms of, 226
definitions for, 225
electron microscopy of, 227–8
immunofluorescence and
immunohistochemistry of, 227
knowledge gaps in, 229
light microscopy of, 226–7
prognosis and therapy of, 228–9
renovascular, 225–6, 228–9
in TSC, 272–4, 279–80
hypoplastic kidneys, 4–5, 11
- I-cell disease, 134–5
- idiopathic nephrotic syndrome (INS),
28–9, 34. *See also* nephrotic
syndrome
- IDMS. *See* isolated diffuse mesangial
sclerosis
- IgA nephropathy (IgAN), 87, 113–14
clinical symptoms of, 88
definition of, 88
gross pathology of, 88
histopathological classification of,
90–1
incidence of, 17–18
microscopic features of, 88–90
pathogenesis of, 88
prognosis of, 91
recurrent, 352, 354
vasculitic, 89, 91–116
- IgA-dominant PIGN, 91, 95
- IgAN. *See* IgA nephropathy
- IgG, in FGN, 164–5
- IgG glomerulopathy, 112, 115
clinical symptoms of, 112
definition of, 112
microscopic features of, 112–13
prognosis and therapy of, 113
- IgM nephropathy (IgMN), 110, 115
clinical symptoms of, 110
definition of, 110
microscopic features of, 110–11
prognosis and therapy of, 110–11
- iliac horns, in NPS, 73–5
- immune complex mediated glomerular
diseases, 87–116
- C1q nephropathy, 99–111, 115
clinical symptoms of, 111
definition of, 111
microscopic features of, 111–12
prognosis and therapy of, 112
- C3GN, 98–100, 114–15
clinical symptoms of, 100
definition of, 99
incidence of, 19
microscopic features of, 94–101
- PIGN compared with, 93
prognosis and therapy of, 101–2
- classification of, 87
- DDD, 96–100, 114–15
clinical symptoms of, 100
definition of, 99
incidence of, 19
microscopic features of, 94–101
- IgAN, 87, 113–14
clinical symptoms of, 88
definition of, 88
gross pathology of, 88
histopathological classification of,
90–1
incidence of, 17–18
microscopic features of, 88–90
pathogenesis of, 88
prognosis of, 91
recurrent, 352, 354
vasculitic, 89, 91–116
- IgG glomerulopathy, 112, 115
clinical symptoms of, 112
definition of, 112
microscopic features of, 112–13
prognosis and therapy of, 113
- IgMN, 110, 115
clinical symptoms of, 110
definition of, 110
microscopic features of, 110–11
prognosis and therapy of, 110–11
- LN, 102, 115
activity and chronicity scoring
system for, 103, 106
classification of, 102–5
clinical symptoms of, 102
definition of, 102
incidence of, 17–18
microscopic features of, 102–6
prognosis and therapy of, 103–5
- MN, 105–6, 115
clinical symptoms of, 107
definition of, 106
incidence of, 17, 19
microscopic features of, 107–9
PIGN compared with, 93
prognosis and therapy of, 109–10
- MPGN, 95–6, 114
clinical symptoms of, 96
definition of, 96–7
diseases associated with, 96
FGN with, 164–5
incidence of, 17–20
microscopic features of, 97–8
prognosis and therapy of, 97–8
recurrent, 352, 354
Trypanosoma infection with, 245
- PIGN, 92, 114
atypical, 93–4
clinical symptoms of, 92
definitions for, 92
endocarditis-associated, 95
gross pathology of, 92–3
IgA-dominant, 91, 95
microscopic features of, 93–4
pathogenesis of, 92
prognosis and therapy of, 93
shunt nephritis, 95
- immunocompromised child,
opportunistic infections in, 248
- adenovirus, 356–7
CMV, 357–8
Cryptococcus neoformans, 247–9
Leishmania donovani, 249–51
polyomavirus nephropathy, 358–61
pyelonephritis, 356
- immunosuppressive drugs
antirejection treatment with, 351
nephrotoxicity of
CNIs, 362–3
m-TOR inhibitors, 363
transplant rejection prevention with,
344
- immunotactoid glomerulopathy (ITG),
159
- inborn errors of metabolism, 121–2, 155.
See also metabolic renal diseases;
mitochondrial kidney disease
- incidence of renal diseases, 17
in allograft biopsies, 23–4
in children versus adults, 17
in native biopsies, 18
glomerular diseases, 18–20
malignant infiltrating disease, 23
monoclonal immunoglobulin-related
diseases, 22–3
non-specific chronic changes, 21–2
normal findings, 18
tubulointerstitial diseases, 20–1
vascular diseases, 21
- incisional biopsy, 342
- INF2* mutations, 44
- infantile polycystic kidney disease. *See*
autosomal recessive polycystic
kidney disease
- infarction, renal, incidence of, 21
- infection. *See also* postinfectious
glomerulonephritis
- acute TIN with, 181–4
ADPKD risk for, 259
direct kidney, 231
bacterial, 231–4
clinical presentation and pathology
of, 233
fungal, 232–3
in immunocompromised child,
249–52

Index

- infection. (cont.)
 parasitic, 231–46
 pathogenesis of, 231
 Rickettsia, 247–8
 spirochetes, 246–7
 viral, 231–41
 hematuria with, 88
 HUS induced by, 220, 222–5
 post-transplant, 248
 adenovirus, 356–7
 CMV, 357–8
 Cryptococcus neoformans, 247–9
 Leishmania donovani, 249–51
 polyomavirus nephropathy, 358–61
 pyelonephritis, 356
 pyelonephritis, 183–7, 247–9, 356
 inheritance
 ADPKD, 256
 of mitochondrial kidney disease, 171–2
 INS. *See* idiopathic nephrotic syndrome
 International Study Group of Fabry
 nephropathy (ISGFN) scoring
 system, 129
 interstitium, 181. *See also*
 tubulointerstitial diseases
 ischemia reperfusion injury, post-
 transplant, 343
 ischemic glomerular collapse, in HTN,
 226–7
 ISGFN scoring system. *See* International
 Study Group of Fabry
 nephropathy scoring system
 isolated diffuse mesangial sclerosis
 (IDMS), 35
 isometric tubular vacuolization,
 calcineurin inhibitor associated,
 362
 ITG. *See* immunotactoid glomerulopathy
 ITGA3 and ITGB4 mutations, 48
 JAG1 mutations, 140–1
 JC virus, 358–61
 juvenile rheumatoid arthritis, 159–63
 KANK1, KANK2 and KANK4 mutations,
 47
 karyomegalic interstitial nephritis (KIN)
 epidemiology, clinical findings and
 etiology of, 190
 light microscopy of, 190
 therapy and prognosis of, 190–1
 Kearns-Sayre syndrome, 49
 kidney
 development of, 1, 13
 anatomical descriptions of, 2
 antenatal ultrasound of, 8
 collecting duct lineage, 3, 6–7
 histology during, 6
 knowledge gaps in, 13
 metanephros, 1–6
 microCT of, 9
 nephron, 3, 5–6, 13
 pronephros and mesonephros, 1–3, 6
 stromal and vascular tissues, 7
 timetable of, 1–2
 functions of, 1
 normal size of, 261–2
 kidney diseases and disorders. *See specific
 topics*
 kidney stones
 APRT deficiency with, 199
 oxalate nephropathy with, 197–8
 kidney transplant pathology. *See*
 transplant pathology
 kidney tumors. *See* tumors
 KIN. *See* karyomegalic interstitial
 nephritis
 knee abnormalities, 73–5
 Lademirsen, 65
 LAMB2 mutations, 35, 66, 77–80
 LAMB2-associated disorder, 78, 80
 laminin $\beta 2$, 77–8
 lecithin-cholesterol acyltransferase
 (LCAT) deficiency, 139–57
 clinical features of, 139–57
 differential diagnosis of, 140
 renal pathological features of, 140–1
 therapy for, 140
 Leigh syndrome, 172–3
Leishmania donovani infections, 249–51
Leptospira infections, 246–7
 lipid and lipoprotein metabolism
 disorders, 122–4
 Alagille syndrome, 140–2
 ApoE2 homozygote glomerulopathy,
 136
 ApoE-related glomerular disorders,
 136–9
 Batten disease, 135–7
 differential diagnosis of, 123–7
 Fabry disease, 123–32
 gangliosidosis, 133, 135
 Gaucher disease, 132–3
 LCAT deficiency, 139–41
 LPG, 136–9
 mucopolidoses, 134–5
 NP disease, 133–56
 lipoprotein glomerulopathy (LPG), 136
 clinical features of, 136
 renal pathological features of, 136–9
 lipoprotein X, 139–57
 liver disease
 in ADPKD, 260, 262
 Alagille syndrome, 140–2
 in ARPKD, 266–7
 LMX1B mutations, 66, 72–4, 76. *See also*
 Nail-Patella syndrome
 LMX1B-associated nephropathy, 74
 LN. *See* lupus nephritis
 loop diuretics, nephrocalcinosis caused
 by, 208
 loop of Henle, 1
 LPG. *See* lipoprotein glomerulopathy
 lump kidneys, 12
 lung hemorrhage, anti-GBM disease with,
 214
 lupus nephritis (LN), 102, 115
 activity and chronicity scoring system
 for, 103, 106
 classification of, 102–5
 clinical symptoms of, 102
 definition of, 102
 incidence of, 17–18
 microscopic features of, 102–6
 prognosis and therapy of, 103–5
 lupus podocytopathy, 103
 lymphoproliferative disorder. *See* post-
 transplant lymphoproliferative
 disorder
 lysosomal storage diseases, 122–3. *See also*
 glycogen, glucoprotein and
 carbohydrate metabolism
 disorders; lipid and lipoprotein
 metabolism disorders
 MAGI2 mutations, 47
 magnetic resonance imaging (MRI), of
 ARPKD, 266
 MAHA. *See* microangiopathic hemolytic
 anemia
 malaria, 243–5
 malignancy. *See* tumors
 malignant hypertension, 225–7, 229
 malignant infiltrating disease, incidence
 of, 23
 malignant rhabdoid tumor of kidney
 (MRTK), 310–33
 malrotation, kidney, 8–12
 mammalian target of rapamycin (mTOR),
 in TSC, 272, 279–80
 maternal factors, in CAKUT
 pathogenesis, 12
 maternal pattern of inheritance, of
 mitochondrial kidney disease,
 171–2
 maturity onset diabetes of the young
 (MODY), 283–4, 295
 McArdle's disease, 144
 MCD. *See* minimal change disease
 MCDK. *See* multicystic dysplastic kidneys
 MCKD. *See* medullary cystic kidney
 disease
 Mediterranean fever, 159–62

Index

- medulla, 1
- medullary cystic kidney disease (MCKD), 290. *See also* autosomal dominant tubulointerstitial kidney disease; nephronophthisis
- MELAS syndrome. *See* mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome
- membrane transport, podocyte, 48
- membranoproliferative glomerulonephritis (MPGN), 95–6, 114. *See also* dense deposit disease
- clinical symptoms of, 96
- definition of, 96–7
- diseases associated with, 96
- FGN with, 164–5
- incidence of, 17–20
- microscopic features of, 97–8
- prognosis and therapy of, 97–8
- recurrent, 352, 354
- Trypanosoma* infection with, 245
- membranous nephropathy (MN), 105–6, 115
- clinical symptoms of, 107
- definition of, 106
- incidence of, 17, 19
- microscopic features of, 107–9
- PIGN compared with, 93
- prognosis and therapy of, 109–10
- membranous-like glomerulopathy with masked IgG kappa deposits, 115
- incidence of, 19
- microscopic features of, 107, 109
- Mendelian pattern of inheritance, of mitochondrial kidney disease, 171–2
- mesangial IgG glomerulopathy. *See* IgG glomerulopathy
- mesangiocapillary glomerulonephritis. *See* membranoproliferative glomerulonephritis
- mesangioproliferative glomerulonephritis (MesGN)
- FGN with, 164–5
- incidence of, 17, 19
- mesonephros, 1–3, 6
- MEST. *See* mixed epithelial and stromal tumor
- MEST-C score, 90–1
- metabolic renal diseases, 121–2, 155
- classification of, 122–3
- glycogen, glucoprotein and carbohydrate metabolism disorders, 122–3, 125
- alkaptonuric ochronosis, 150–1
- CGD, 145–6
- childhood obesity and metabolic syndrome, 148, 150
- diabetes mellitus in childhood and adolescence, 146–9
- galactosialidosis, 143–4
- GSD, 143–5
- MMA, 148–50
- nephrosialidosis, 141–3
- hemoglobinopathies, 151–5
- knowledge gaps in, 155
- lipid and lipoprotein metabolism disorders, 122–4
- Alagille syndrome, 140–2
- ApoE2 homozygote glomerulopathy, 136
- ApoE-related glomerular disorders, 136–9
- Batten disease, 135–7
- differential diagnosis of, 123–7
- Fabry disease, 123–32
- gangliosidosis, 133, 135
- Gaucher disease, 132–3
- LCAT deficiency, 139–41
- LPG, 136–9
- mucopolidoses, 134–5
- NP disease, 133–56
- renal Fanconi syndrome, 122
- metabolic syndrome, childhood, 148, 150
- metanephric dysplasia, in TSC, 275–6
- metanephric tumors, 331–3
- metanephros, 1–6
- metastatic calcifications. *See* nephrocalcinosis
- methylmalonic acidemia (MMA), 148
- clinical and pathologic features of, 149–50
- therapy for, 150
- methylprednisolone, antirejection treatment with, 351
- microangiopathic hemolytic anemia (MAHA), 220
- microcoria-congenital nephrosis syndrome. *See* Pierson syndrome
- microCT, of CAKUT, 9
- microcysts, in TSC, 275, 277
- microhamartoma, in TSC, 275
- microscopic polyangiitis (MPA), 213–18
- minimal change disease (MCD), 27–8, 34
- ancillary laboratory tests for, 31–3
- biopsy incidence of, 17–18
- clinical symptoms of, 29
- definition of, 28–9
- HIVAN with, 235–7
- knowledge gaps in, 34–5
- microscopy and immunofluorescence of, 29–33
- prognosis and therapy of, 33–4
- miTF* rearrangements, 325–7
- MITKD. *See* mitochondrially inherited tubulointerstitial kidney disease
- mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) syndrome, 172–3, 175
- mitochondrial kidney disease, 171, 178
- clinical symptoms of, 172–4
- coenzyme Q2 deficiency, 175
- definitions for, 171
- genetics of, 171–3
- homoplasmy and heteroplasmy in, 172
- inheritance patterns of, 171–2
- isolated kidney dysfunction, 174–5
- microscopic features of, 175–7
- treatment, prognosis and future perspectives of, 176–8
- mitochondrially inherited tubulointerstitial kidney disease (MITKD), 174–8
- mixed epithelial and stromal tumor (MEST), 327–8
- MMA. *See* methylmalonic acidemia
- MN. *See* membranous nephropathy
- MODY. *See* maturity onset diabetes of the young
- molecular pathology. *See* genetics
- monoclonal immunoglobulin-related diseases, incidence of, 22–3
- motility genes, podocyte, 44–8
- mouse, as nephrogenesis model, 1–2, 13
- MPA. *See* microscopic polyangiitis
- MPGN. *See* membranoproliferative glomerulonephritis
- MRI. *See* magnetic resonance imaging
- MRTK. *See* malignant rhabdoid tumor of kidney
- MT-CO1* mutations, 173–4
- mTOR. *See* mammalian target of rapamycin
- m-TOR inhibitors, nephrotoxicity of, 363
- MT-TF* mutations, 174–5
- MUC1* mutations, 290–6
- mucopolidoses, 134
- clinical features of, 135
- definitions and pathogenesis of, 134
- pathologic features of, 135
- multicystic dysplastic kidneys (MCDK), 4–5, 8–12
- multipapillary kidneys, 1
- MUT* mutations, 148
- Mycobacterium tuberculosis* infections, 231–4
- mycophenolate mofetil, 344
- myelin and zebra bodies, 128, 131
- MYH9* mutations, 44–6, 66
- MYH9*-related syndrome, 65–78
- MYO1E* mutations, 47

Index

- myoglobin cast nephropathy, 197, 209
clinical symptoms of, 199–200
light microscopy of, 202–5
prognosis and therapy of, 208
- N-acetylglucosamine
1 phosphotransferase deficiency, 134
- Nail Patella-like renal disease, 74
- Nail-Patella syndrome (NPS), 27–46, 72–3, 77
clinical findings of, 73–5
definition of, 73
genetics of, 65–78
knowledge gaps in, 77
renal histopathology of, 74–6
treatment and monitoring of, 76–7
- Narsoplimab, 222–5
- NCL. *See* neuronal ceroid lipofuscinoses
- necrotizing granulomas, tuberculosis, 231–4
- necrotizing vasculitis. *See* ANCA-associated vasculitis; anti-GBM disease
- NEIL1* mutations, 48
- NELL1 antigen, 105–6
- neonatal nephrocalcinosis, 198–9, 208
- neoplasm. *See* tumors
- NEP antibodies, 105–6
- nephrin, 37, 40
- nephroblastoma. *See* Wilms' tumor
- nephroblastomatosis, 312–13
- nephrocalcinosis, 188–9, 197, 209
clinical symptoms of, 198–9
incidence of, 20–1
light microscopy of, 202–3
prognosis and therapy of, 208
- nephrogenesis, 1, 13
anatomical descriptions of, 2
antenatal ultrasound of normal and abnormal, 8
collecting duct lineage, 3, 6–7
histology during, 6
knowledge gaps in, 13
metanephros, 1–6
microCT of normal and abnormal, 9
nephron, 3, 5–6, 13
pronephros and mesonephros, 1–3, 6
stromal and vascular tissues, 7
timetable of, 1–2
- nephrogenic rests (NR), 312–13
- nephrolithiasis. *See* kidney stones
- nephron, 1
normal development of, 3, 5–6, 13
- nephron endowment, 1, 13
- nephronophthisis (NPH), 290–1, 296
clinical symptoms and histopathology of, 290–2, 294
definition of, 290
gross pathology of, 295
incidence of, 21
knowledge gaps in, 296–7
microscopic features of, 291–5
prognosis and therapy of, 296
- nephrosialidosis, 141–2
clinical features of, 142
renal pathologic features of, 143
therapy for, 143
- nephrotic syndrome (NS), 27. *See also* congenital nephrotic syndrome
CGP with, 18–19, 30–1, 41–3
DMS with, 18–19, 33–7, 78–9
genetics of, 27–46, 49
autosomal dominant conditions, 44–7
autosomal recessive conditions, 47–9
knowledge gaps in, 49
MCD and FSGS with, 17–19, 27–35
mitochondrial disease with, 175–6
- nephrotic syndrome type 5 (NPHS5), 78
- nephrotoxicity, immunosuppressive drug CNIs, 362–3
m-TOR inhibitors, 363
- NEU1* mutations, 141–2
- neuronal ceroid lipofuscinoses (NCL), 135–7
- Niemann-Pick (NP) disease, 133
clinical features of, 133
pathological features of, 133–4
- nifurtimox, 246
- NOS subtype FSGS, 30–3
- Notch signaling pathway (NSP), in Alagille syndrome, 140–1
- NP disease. *See* Niemann-Pick disease
- NPH. *See* nephronophthisis
- NPHS1* mutations, 37–41
- NPHS2* mutations, 37–41
- NPHS5. *See* nephrotic syndrome type 5
- NPS. *See* Nail-Patella syndrome
- NR. *See* nephrogenic rests
- NS. *See* nephrotic syndrome
- NSAID-induced TIN, 181–3
- NSP. *See* Notch signaling pathway
- nucleoside/nucleotide reverse transcriptase inhibitors, 176
- obesity
childhood, 148, 150
incidence of glomerulopathy related to, 20
maternal, 12
- ochronosis, alkaptonuric, 150–1
- OCRL mutations, 48
- ocular abnormalities
in Alport syndrome, 59–63
in Pierson syndrome, 77–8
- oligohydramnios
ADPKD with, 260–1
ARPKD with, 265
- oligomeganephronia, 11
- open biopsy, 342
- opportunistic infections, 248
adenovirus, 356–7
CMV, 357–8
Cryptococcus neoformans, 247–9
Leishmania donovani, 249–51
polyomavirus nephropathy, 358–61
pyelonephritis, 356
- organic acid disorders
alkaptonuric ochronosis, 150–1
MMA, 148–50
- Orientia tsutsugamushi*, direct kidney infections with, 247–8
- ossifying renal tumor (ORT), 333
- Osterreicher-Turner Syndrome. *See* Nail-Patella syndrome
- oxalate nephropathy, 21, 197, 209
clinical symptoms of, 197–8
light microscopy of, 201–2
prognosis and therapy of, 207–8
recurrent, 352, 354
- Oxford Classification of IgAN, 90–1
- parasites, direct kidney infections with, 231–3
Plasmodium, 243–5
Schistosoma, 241–3
Trypanosoma, 245–6
- parietal epithelial cell (PEC) markers, 31–3
- Parvovirus B19* (PVB19), 237–8, 248
- patella abnormalities, 73–5
- PAX2* mutations, 11, 47, 66
- PAX6* mutations, 300
- PC1 and PC2. *See* polycystin 1 and 2
- PCN. *See* pediatric cystic nephroma
- PDSS2* mutations, 48
- Pearson syndrome, 49
- PEC markers. *See* parietal epithelial cell markers
- pediatric cystic nephroma (PCN), 314–16, 327–31
- pediatric inflammatory multisystem syndrome (PIMS), 225
- pediatric kidney transplantation. *See* transplant pathology
- pediatric metanephric tumors, 331–3
- pediatric renal tumors. *See* tumors
- perihilar subtype FSGS, 30–3
- peri-implantation biopsy, 342–3
- Perlman syndrome, 300–3
- PGNMIID. *See* proliferative glomerulonephritis with monoclonal immunoglobulin deposits

- Pierson syndrome, 27–46, 77, 80
 clinical symptoms of, 78
 definition of, 77
 genetics of, 65–80
 knowledge gaps in, 80
 pathology of, 78–9
 treatment, monitoring, and prognosis of, 80
- pigment deposits, tubulointerstitial diseases with, 197, 209
 clinical symptoms of, 199
 definitions for, 197
 gross pathology of, 201
 knowledge gaps in, 209
 light microscopy of, 202–7
 prognosis and therapy of, 208–9
- PIGN. *See* postinfectious glomerulonephritis
- PIMS. *See* pediatric inflammatory multisystem syndrome
- PKD1* and *PKD2* mutations, 255–8, 272
- PKHD1* mutations, 256, 264–6
- PLA2R* antigen, 105–6
- Plasmodium* infections, 243–5
- PLCE1* mutations, 35, 47
- PLD. *See* polycystic liver disease
- PNET. *See* primitive neuroectodermal tumor
- podocin, 37, 39–40
- podocytes, 27, 37
 molecular pathology involving
 actin-binding complexes, slit membrane signaling and podocyte motility genes, 44–8
 additional disorders, 48–9
 calcium signaling genes, 46–7
 coenzyme Q₁₀ biosynthesis, 48
 membrane transport genes, 48
 transcription factors and DNA-interacting proteins, 47–8
- podocytopathies. *See* proteinuric glomerular diseases
- polycystic kidney diseases. *See also* autosomal dominant polycystic kidney disease; autosomal recessive polycystic kidney disease
 TSC, 275–6, 278
- polycystic liver disease (PLD), 260
- polycystin 1 and 2 (PC1 and PC2), 256–7
- polyomavirus (PyV) nephropathy, 358–61
- postinfectious glomerulonephritis (PIGN), 92, 114
 atypical, 93–4
 clinical symptoms of, 92
 definitions for, 92
 endocarditis-associated, 95
 gross pathology of, 92–3
 IgA-dominant, 91, 95
 microscopic features of, 93–4
 pathogenesis of, 92
 prognosis and therapy of, 93
 shunt nephritis, 95
- post-streptococcal GN (PSGN), 92
- post-transplant complications. *See* transplant pathology
- post-transplant lymphoproliferative disorder (PTLD), 361–2
- Potter's sequence, 9, 260–1, 265
- PPCA deficiency. *See* protective protein/cathepsin deficiency
- prednisone, for nephrotic syndrome, 33–4
- pregnancy, Nail-Patella syndrome
 exacerbation by, 74
- preterm infants, nephrocalcinosis in, 198–9, 208
- primitive neuroectodermal tumor (PNET), primary renal, 310–33
- proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), incidence of, 22–3
- pronephros, 1–3, 6
- protective protein/cathepsin (PPCA) deficiency, 143
- proteinuria, cutoffs for, 27
- proteinuric glomerular diseases, 27
 CGP, 41, 43
 ancillary laboratory tests for, 42–3
 clinical symptoms of, 41
 collapsing subtype FSGS, 30–1
 definitions for, 41
 HIVAN with, 41–2, 235–7
 incidence of, 18–19
 knowledge gaps in, 43
 microscopy and immunofluorescence of, 41–2
 mitochondrial disease with, 175–6
 prognosis and therapy of, 43
 PVB19-associated, 237–8
- CNS, 37, 41
 ancillary laboratory tests for, 40
 clinical symptoms of, 39
 definitions for, 37–9
 knowledge gaps in, 41
 microscopy and immunofluorescence of, 38–40
 prognosis and therapy of, 40–1
 syphilis with, 247
- DMS, 18–19, 33–7
 clinical symptoms of, 35
 definitions for, 35
 knowledge gaps in, 37
 microscopy and immunofluorescence of, 35–7
 in Pierson syndrome, 78–9
 prognosis and therapy of, 37
- genetics of, 27–46, 49
 autosomal dominant conditions, 44–7
 autosomal recessive conditions, 47–9
 knowledge gaps in, 49
 incidence of, 18–19
 lupus, 103
 MCD and FSGS, 27–8, 34
 ancillary laboratory tests for, 31–3
 biopsy incidence of, 17–19
 clinical symptoms of, 29
 definitions of, 28–9
 HIVAN with, 235–7
 knowledge gaps in, 34–5
 microscopy and immunofluorescence of, 29–33
 prognosis and therapy of, 33–4
- proximal tubule, 1
 membrane transport in, 48
 normal development of, 3, 5–6
- PSGN. *See* post-streptococcal GN
- PTLD. *See* post-transplant lymphoproliferative disorder
- PTPRO* mutations, 47–8
- pulmonary hypoplasia
 ADPKD with, 260–1
 ARPKD with, 265
- pulmonary-renal syndrome, anti-GBM disease presenting as, 214
- PVB19. *See* Parvovirus B19
- pyelonephritis
 cryptococcal, 247–9
 definitions for, 183–5
 epidemiology, clinical findings and etiology of, 185
 light microscopy of, 185–7
 post-transplant, 356
 therapy and prognosis of, 187
- PyV nephropathy. *See* polyomavirus nephropathy
- quartan malarial nephropathy, 244
- rapamycin, 279–80, 363
- rapidly progressive glomerulonephritis (RPGN), 214
- RAS system. *See* renin-angiotensin-aldosterone system
- RBC casts. *See* red blood cell casts
- RCAD. *See* renal cysts and diabetes syndrome
- RCC. *See* renal cell carcinoma
- RCS. *See* renal coloboma syndrome
- red blood cell (RBC) casts, 197, 209
 clinical symptoms of, 200
 light microscopy of, 205–6
 prognosis and therapy of, 208

Index

- reflux nephropathy, 183–7. *See also* pyelonephritis
- rejection, transplant
 Banff classification of, 345
 histopathological scores according to revised 2019, 345–50
 polyomavirus nephropathy, 359–61
 rejection categories according to revised 2019, 350–1
 distribution of allograft biopsies with, 23–4
 immunologic background and mechanisms of, 344
 antibody-mediated, 345
 T cell-mediated, 345
- REN* mutations, 290–1, 294–6
- renal agenesis or aplasia, 4–5, 8–9
- renal artery stenosis, 225–6
- renal cell carcinoma (RCC), 325–7
 in TSC, 272–4, 277
- renal coloboma syndrome (RCS), 11, 47, 65–78
- renal cortex, 1
- renal cysts. *See* cystic kidney diseases
- renal cysts and diabetes syndrome (RCAD), 11–12
- renal diseases and disorders. *See specific topics*
- renal dysplasia, 4–5, 8–12, 286–7
- renal ectopias, 10–11
- renal Fanconi syndrome, 122
- renal medulla, 1
- renal medullary carcinoma (RMC), 323–5
- renal tubular dysgenesis
 epidemiology, clinical findings and etiology of, 191
 microscopy and immunofluorescence of, 191–2
 therapy and prognosis of, 191
- renal tumors. *See* tumors
- renin-angiotensin-aldosterone (RAS) system, absence of functional, 191–2
- renovascular hypertension (RVH), 225–6, 228–9
- retinitis pigmentosa (RP), 285–9
- retinoic acid, 12
- retinopathy, in Alport syndrome, 59–63
- rhabdoid tumors, malignant of kidney, 310–33
- rhabdomyolysis. *See* myoglobin cast nephropathy
- Rickettsia* infections, 247–8
- rituximab, 219, 351
- RMC. *See* renal medullary carcinoma
- Rocky mountain spotted fever (RMSF), 247–8
- RP. *See* retinitis pigmentosa
- RPGN. *See* rapidly progressive glomerulonephritis
- RVH. *See* renovascular hypertension
- SAA. *See* serum amyloid A
- Sandhoff disease, 133
- sarcoidosis
 epidemiology, clinical findings and etiology of, 188
 light microscopy of, 188–9
 therapy and prognosis of, 189
- SARS-CoV-2. *See* severe acute respiratory syndrome coronavirus 2
- SCARB2 mutations, 48
- SCDs. *See* sickle cell disorders
- Schistosoma* infections, 241–3
- scrub typhus, 247–8
- SDNS. *See* steroid-dependent nephrotic syndrome
- SEC61A1* mutations, 290–1, 295
- segmental sclerosis. *See also* focal segmental glomerulosclerosis
 in AAV and anti-GBM disease, 213–19
 in IgAN, 88–91
- SEMA3B antigen, 105–6
- serum amyloid A (SAA), 159–62
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
 direct kidney infections with, 240–1
 nephropathy associated with, 18–19, 41–2
 TMA with, 225
- SGPL1* mutations, 48
- Shiga-toxin HUS, 220, 222–5
- shunt nephritis, 95
- sialidosis. *See* galactosialidosis; nephrosialidosis
- sickle cell disorders (SCDs), 151–2
 clinical features of, 152
 renal pathological features of, 152–5
- sirolimus, 279–80
- SIX1* and *SIX5* mutations, 66
- size mismatch glomerulopathy, 354
- Sjögren's syndrome, 189
- SLE. *See* systemic lupus erythematosus
- slit diaphragms, 27, 37
- slit membrane signaling, 44–8
- SMARCA4* mutations, 321–3
- SMARCAL1* mutations, 47
- SMARCB1* mutations, 321–5
- solid kidney tumors, 299. *See also* Wilms' tumor
 ASK, 327–31
 CCSK, 310–33
 CMN, 310–33
 CPDN, 314–30
 differential diagnosis of, 310–33
- kidney disease associated with treatment of, 333–4
- MRTK, 310–33
- ORTI, 333
- PCN, 314–16, 327–31
- pediatric metanephric tumor, 331–3
- PNET, 310–33
- rare miscellaneous, 333
- RCC, 272–4, 277, 325–7
- RMC, 323–5
- Spielmayer-Vogt- Sjogren disease, 135–6
- spirochete infections, 246–7
- SRNS. *See* steroid resistant nephrotic syndrome
- SSNS. *See* steroid sensitive nephrotic syndrome
- Staphylococcus aureus*. *See* acute post *Staphylococcus aureus* GN
- steroid resistant nephrotic syndrome (SRNS), 27
 CNS, 38, 40
 DMS, 35
 MCD and FSGS, 28, 34
 clinical symptoms of, 29
 definition of, 28–9
 knowledge gaps in, 34–5
 prognosis and therapy of, 33–4
 steroid sensitive nephrotic syndrome (SSNS), 27
 MCD and FSGS, 28, 34
 clinical symptoms of, 29
 definition of, 28–9
 knowledge gaps in, 34–5
 prognosis and therapy of, 33–4
 steroid therapy
 for acute TIN, 183
 antirejection treatment with, 351
 for nephrotic syndrome, 33–4
 transplant rejection prevention with, 344
- steroid-dependent nephrotic syndrome (SDNS), 28–9, 33–4
- Streptococcus pyogenes*. *See* post-streptococcal GN
- stromal tissues, normal development of, 7
- subacute necrotizing encephalomyopathy. *See* Leigh syndrome
- SV40 virus, 358–61
- syphilis, 247
- systemic lupus erythematosus (SLE), 102, 189. *See also* lupus nephritis
- T cell-mediated rejection (TCMT)
 Banff classification of, 351
 distribution of allograft biopsies with, 23–4
 immunologic background and mechanisms of, 345

- tacrolimus, 344, 362–3
 TB. *See* tuberculosis
TBC1D8 mutations, 48
 TBMN. *See* thin basement membrane nephropathy
 TCC. *See* terminal complement complex
TCF2 gene, 11
 TCMT. *See* T cell-mediated rejection
 teratogens, in CAKUT pathogenesis, 12
 terminal complement complex (TCC), 220, 222–5
TFE3 mutations, 325–7
TFEB mutations, 325–7
 TGP. *See* transplant glomerulopathy
 thin basement membrane nephropathy (TBMN), 67, 72
 clinical symptoms of, 67–9
 definition of, 67
 genetics of, 71–2
 incidence of, 19
 knowledge gaps in, 72
 microscopy and immunofluorescence of, 65, 69–71
 prognosis and therapy of, 72
 thioflavin T and S stain, 162
 threshold effect, in mitochondrial kidney disease, 172
 thrombosis, post-transplant, 343
 thrombotic microangiopathy (TMA), 220, 225
 calcineurin inhibitor associated, 362–3
 clinical symptoms of, 220
 definitions for, 220
 electron microscopy of, 221–2
 immunofluorescence and immunohistochemistry of, 221–2
 incidence of, 21
 knowledge gaps in, 225
 light microscopy of, 220–2
 pathophysiology of, 220
 pediatric tumor treatment associated with, 333–4
 prognosis and therapy of, 222–5
 thrombotic thrombocytopenic purpura (TTP), 220, 225
 clinical symptoms of, 220
 definitions for, 220
 electron microscopy of, 221–2
 immunofluorescence and immunohistochemistry of, 221–2
 incidence of, 21
 knowledge gaps in, 225
 light microscopy of, 220–2
 pathophysiology of, 220
 prognosis and therapy of, 222–5
 THSD7A antigen, 105–6
 TIN. *See* tubulointerstitial nephritis
 TINU. *See* tubulointerstitial nephritis with uveitis
 tip subtype FSGS, 30–3
 TKV. *See* total kidney volume
 TMA. *See* thrombotic microangiopathy
 tolvaptan, 263
 total kidney volume (TKV)
 in ADPKD, 258–62
 in ARPKD, 267
TP53 mutations, 306–9, 314
 transcription factors, podocyte, 47–8
 transplant biopsy
 distribution of diagnoses made with, 23–4
 processing of, 342–3
 types of, 341–2
 transplant glomerulopathy (TGP), 352–3
 transplant pathology, 341, 363. *See also* rejection, transplant
 de novo diseases, 352–6
 immunosuppressive drug nephrotoxicity
 CNIs, 362–3
 m-TOR inhibitors, 363
 infection, 248
 adenovirus, 356–7
 CMV, 357–8
 Cryptococcus neoformans, 247–9
 Leishmania donovani, 249–51
 polyomavirus nephropathy, 358–61
 pyelonephritis, 356
 ischemia reperfusion injury, 343
 knowledge gaps in, 363
 PTLD, 361–2
 recurrent disease, 352–4
 surgical complications, 343
Treponema pallidum infection, 247
 tropical infections, 231
 bacterial, 231, 233
 parasitic, 231, 233
 viral, 231, 233
TRPC6 mutations, 46–7
Trypanosoma infections, 245–6
 TSC. *See* tuberous sclerosis complex
TSC1 and *TSC2* mutations, 272
TSC2/PKD1 contiguous gene syndrome, 272
 Tsutsugamushi disease, 247–8
TTC21B mutations, 48
 TTP. *See* thrombotic thrombocytopenic purpura
 tuberculosis (TB), 231–4, 248
 tuberin, 272, 277–9
 tuberous sclerosis complex (TSC), 272, 280
 ancillary laboratory tests for, 277–9
 clinical symptoms of, 272–4
 definitions for, 272
 diagnostic criteria for, 272
 gross pathology of, 274–5
 knowledge gaps in, 280
 microscopic features of, 274–8
 prognosis and therapy of, 279–80
 tubules, 1, 181
 membrane transport in, 48
 normal development of, 3, 5–6
 tubulointerstitial diseases
 ADTKD, 190, 290, 296
 clinical symptoms and histopathology of, 291–5
 definition of, 290
 genetics of, 290–5
 gross pathology of, 295
 knowledge gaps in, 296–7
 microscopic features of, 293, 295–6
 mitochondrial kidney disease compared with, 176
 prognosis and therapy of, 296
 with crystal and pigment deposits, 197, 209
 clinical symptoms of, 197–201
 definitions for, 197
 gross pathology of, 201
 knowledge gaps in, 209
 light microscopy of, 201–7
 prognosis and therapy of, 206–9
 de novo post-transplant, 355–6
 incidence of, 20–1
 metabolic disease with, 121–2
 mitochondrial disease with, 174–8
 NPH, 290–1, 296
 clinical symptoms and histopathology of, 290–2, 294
 definition of, 290
 gross pathology of, 295
 incidence of, 21
 knowledge gaps in, 296–7
 microscopic features of, 291–5
 prognosis and therapy of, 296
Trypanosoma infection, 245–6
 tubulointerstitial nephritis (TIN), 181–9, 193
 acute and allergic
 epidemiology, clinical findings and etiology of, 181–2
 microscopy and immunofluorescence of, 182–4
 therapy and prognosis of, 183
 autoimmune, 189
 chronic, 182, 190
 definitions for, 181
 hereditary, 190
 ADTKDs, 176, 190
 Bartter's syndrome, 191–3
 KIN, 190–1
 renal tubular dysgenesis, 191–2

Index

- tubulointerstitial nephritis (TIN) (cont.)
 knowledge gaps in, 194
 pyelonephritis
 definitions for, 183–5
 epidemiology, clinical findings and etiology of, 185
 light microscopy of, 185–7
 therapy and prognosis of, 187
 sarcoidosis
 epidemiology, clinical findings and etiology of, 188
 light microscopy of, 188–9
 therapy and prognosis of, 189
 tubulointerstitial nephritis with uveitis (TINU)
 epidemiology, clinical findings and etiology of, 187–8
 light microscopy of, 188
 therapy and prognosis of, 188
 tumors. *See also* solid kidney tumors
 TSC, 272–4
 ancillary laboratory tests for, 277–9
 gross pathology of, 274–5
 microscopic features of, 274–8
 treatment of, 279–80
 Turner-Kieser syndrome. *See* Nail-Patella syndrome
 type III collagenopathy, 80–1, 83, 159, 166
 clinical symptoms of, 81, 166
 knowledge gaps in, 83
 pathogenesis of, 166
 pathology of, 81–3, 166–8
 prognosis and therapy of, 83, 167
 type III hyperlipoproteinemia, 136
 typhus, 247–8
- UAKD. *See* uromodulin-associated kidney disease
 ubiquinone. *See* coenzyme Q₁₀
 ultrasonography
 of ADPKD, 259–60
 of ARPKD, 266
 of CAKUT, 8
 UMOD mutations, 290–3, 295–6
 ureteric bud, 2–7, 11–12
 urinary tract infection (UTI), 185. *See also* pyelonephritis
 urinary tract obstruction, 186–7
- urolithiasis, oxalate nephropathy with, 197–8
 uromodulin-associated kidney disease (UAKD), 290–3, 295–6
 UTI. *See* urinary tract infection
 uveitis. *See* tubulointerstitial nephritis with uveitis
- vascular diseases, 213. *See also* hypertension
 AAV and anti-GBM disease, 219
 ancillary laboratory tests for, 219
 classification and scoring of, 219
 clinical symptoms of, 214
 definitions for, 213
 electron microscopy of, 215, 218–19
 immunofluorescence and immunohistochemistry of, 214–18
 knowledge gaps in, 220
 light microscopy of, 214–18
 pathophysiology of, 213–14
 prognosis and therapy of, 219
 incidence of, 21
 metabolic disease, 121–2
 TMA, 220, 225
 calcineurin inhibitor associated, 362–3
 clinical symptoms of, 220
 definitions for, 220
 electron microscopy of, 221–2
 immunofluorescence and immunohistochemistry of, 221–2
 knowledge gaps in, 225
 light microscopy of, 220–2
 pathophysiology of, 220
 pediatric tumor treatment associated with, 333–4
 prognosis and therapy of, 222–5
 vascular occlusion, SCDs with, 151–5
 vascular thrombosis, post-transplant, 343
 vascular tissues, normal development of, 7
 vasculitis, IgA, 89, 91–116
 vasculopathy, Fabry disease with, 128–9, 132
 VCL-ALK fusion RCCs, 326
 ventriculoatrial shunt related GN, 95
 vesicoureteral reflux (VUR), 183–5
 vilobelimab, 213–14
- viruses
 direct kidney infections with, 231–5, 241
 dengue virus, 239–40
 Hantaviruses, 231–9
 HIV, 235–7
 PVB19, 237–8
 SARS-CoV-2, 240–1
 post-transplant infection with, 248
 adenovirus, 356–7
 CMV, 357–8
 polyomavirus, 358–61
 vitamin A, 12
 von Gierke disease, 144–5
 von Kossa stain, 197, 201–2
 von Willebrand disease, 304–12
 VUR. *See* vesicoureteral reflux
- WAGR syndrome, 300, 302
 wedge biopsy, 342
 Wegener's granulomatosis. *See* granulomatosis with polyangiitis
 Williams-Beuren syndrome, 20–1
 Wilms' tumor (WT), 299, 314
 bilateral, 300
 clinical symptoms and pathologic diagnosis of, 303–33
 CPDN compared with, 314–16
 definitions for, 300–12
 extra-renal, 300–12
 genetics and associated syndromes of, 299–303
 nephrogenic rests and nephroblastomatosis compared with, 312–13
 risk stratification, staging, and histological grading of, 301–2, 306–14
 treatment and knowledge gaps of, 312–14
 Wolffian duct. *See* mesonephros
 WT. *See* Wilms' tumor
 WT1 mutations, 35, 47, 300–3
- xanthogranulomatous pyelonephritis, 187
 X-linked Alport syndrome, 57–9
 clinical symptoms of, 59–60
 collagen IVα5 staining in, 61–4, 68
 TBMN compared with, 65, 67, 69, 71